Module 4: (Part 1) Development of Biologics for CNS Diseases, and (Part 2) The Art of CNS Drug Development: Delivery Strategies, Neurotoxicology Endpoints, and Regulatory Considerations

Recorded On: 05/16/2024

image
image


Part 1: Development of Biologics for CNS Diseases

Nonclinical Safety Assessment of Galcanezumab, a CGRP Monoclonal Antibody for the Treatment of Migraine. Emgality® (galcanezumab) is included as a case study of the nonclinical development of biologics for CNS diseases. Galcanezumab is a humanized IgG4 monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand with high affinity and selectivity and blocks its binding to the receptor. Elevated blood concentrations of CGRP, a potent vasodilator, have been associated with migraine attacks. Galcanezumab was approved by the US FDA in 2018 and is marketed under the tradename “Emgality®”, for the preventive treatment of migraine and for treatment of episodic cluster headache in the US.

The nonclinical safety assessment for galcanezumab was designed and conducted according to regulatory guidance (e.g., ICH S5, S6) and GLP guidelines. Galcanezumab is pharmacologically active in rats and rabbits, and the CGRP sequence in monkeys is identical to that in humans. The high doses in the toxicology studies were selected according to ICH S6 criteria: saturation of PD and exposures ̴10X in excess of human recommended doses. The clinical route of administration (subcutaneous) was used, and the dose regimens (QW or more frequently) were chosen to maintain exposure over the treatment periods.

The presentation will focus on the nonclinical safety package consisting of: 1) repeated-dose toxicology studies in rats and monkeys (SC, QW) up to 6 months, with safety pharmacology parameters (CNS, Respiratory, and Cardiovascular, CV) incorporated in the monkey studies; 2) a full developmental and reproductive toxicology package in rats including male fertility, female fertility, and early embryonic development, embryofetal development (also rabbits), and pre- and postnatal development; and 3) a juvenile toxicology study in rats. Genetic toxicology studies were not required, and carcinogenicity was assessed using a weight-of-evidence evaluation. Dose selection for initial clinical trials was based on in vitro characterization (binding affinity, selectivity, and functionality of binding to CGRP) and an in vivo model of capsaicin-induced increases in dermal blood flow (a PD biomarker of CGRP pathway modulation). Of topical interest to regulators were: 1) high dose selection/justification; and 2) the impact of long-term antagonism of CGRP in humans, particularly in patients with CV risk factors (a theoretical concern considered low based on comprehensive reviews of the literature and data).

Part 2: The Art of CNS Drug Development: Delivery Strategies, Neurotoxicology Endpoints, and Regulatory Considerations

The session will present and discuss central nervous system (CNS) drug delivery in preclinical species along with toxicology, translational, and regulatory considerations relevant to these specialized modalities. Fundamental and advanced neurotoxicity endpoints will be reviewed and contrasted as early and late drug development phases are presented. The session will address neurotoxicology concepts that may serve to design or interpret toxicology studies with CNS delivery.

Simon Authier, DVM, MSc, MBA, PhD, DSP

Simon Authier, DVM, MSc, MBA, PhD, DSP

Executive Director of Scientific Innovation and Partnerships

Charles River Laboratories

Dr. Simon Authier obtained a Doctor of Veterinary Medicine degree from the University of Montreal and specialized in nonclinical studies after completing a PhD in nonclinical pharmacology. He then completed an MBA in corporate finance and management. Dr. Authier is an Executive Director of Scientific Innovation and Partnerships at Charles River Laboratories, where he leads drug development programs across a broad range of modalities. He has been an invited speaker at various scientific conferences, including the American College of Toxicology, the Safety Pharmacology Society, the Japanese Society of Safety Pharmacology, the American Association of Laboratory Animal Science, and the US Food and Drug Administration. Dr. Authier is an Associate Professor at the Faculty of Veterinary Medicine at the University of Montreal, where he is involved with clinical immunology and pharmacology, and he has authored more than 150 peer-reviewed articles and book chapters. To date, Dr. Authier has provided scientific overviews for more than 1,400 nonclinical studies for small molecules, biologics, and cell therapies. He is a past President of the Safety Pharmacology Society (SPS), is a board-certified safety pharmacologist (DSP), and currently serves as the ACT Secretary. Over the years, he has volunteered and participated in various ACT initiatives, including educational sessions.

Lorrene A. Buckley, PhD, DABT, ATS

Lorrene A. Buckley, PhD, DABT, ATS

Vice President

Eli Lilly & Company

Dr. Lorrene Buckley is a board-certified toxicologist with over 30 years of experience in the active practice of toxicology. She earned her degrees in Toxicology, an MS from the University of Arizona, and a PhD from the University of North Carolina at Chapel Hill, in collaboration with the laboratories of the NIEHS and US EPA. She is certified by the American Board of Toxicology (ABT) and is a Fellow of the Academy of Toxicological Sciences (ATS).

Dr. Buckley’s diversity of professional experience as a toxicologist is reflected in her work spanning basic and applied toxicology research and risk assessment in the industrial chemical, agrochemical, and pharmaceutical industries. As a Vice President at Eli Lilly & Company, she was responsible for the design and execution of nonclinical safety assessment programs as well as for nonclinical aspects of global regulatory submissions and interactions for drugs in the development and commercialization phases. Dr. Buckley has authored the pharmacology/toxicology sections of numerous regulatory documents, including briefing documents, INDs/IMPDs, BLAs/NDAs, investigator brochures, annual reports, as well as safety information on product labels/package inserts.

Her contributions to the profession of toxicology include service on the Boards of the ABT and the ATS (past President) and on the Councils of the ACT (past President) and the SOT.

Key:

Complete
Failed
Available
Locked
Module 4 (Part 1) Development of Biologics for CNS Diseases, and (Part 2) The Art of CNS Drug Development: Delivery Strategies, Neurotoxicology Endpoints, and Regulatory Considerations
Module 4: (Part 1) Development of Biologics for CNS Diseases, Lorrene Buckley, PhD, DABT, ATS, and (Part 2) The Art of CNS Drug Development: Delivery Strategies, Neurotoxicology Endpoints, and Regulatory Considerations, Simon Authier, DVM, MSc, MBA, PhD,
Recorded 05/16/2024  |  90 minutes
Recorded 05/16/2024  |  90 minutes As part of your registration, you will have unlimited access to the module recording for 30 days. Your 30-day access period begins when you first access the recording. Once the access period begins, it cannot be reset or restarted. To receive a certificate of completion, you must watch the recording for the minimum required viewing time. Please keep the recording open while viewing, as the system tracks your viewing time during the active session. If you close your browser before meeting the minimum viewing requirement, your viewing progress may not be retained. Once you have met the viewing requirement, the module survey will become available. After completing the survey, you will be able to access and download your certificate of completion. If you have any questions, please contact ACT Headquarters at [email protected].
Survey
13 Questions
13 Questions ACT values your feedback. Please help us continue to provide high-quality educational offerings by completing this short survey. The survey will become available after you have met the minimum viewing requirement for the recording. Once you complete the survey, your certificate of completion will become available on your dashboard or for download.
Certificate
No credits available  |  Certificate available
No credits available  |  Certificate available Your certificate of completion will become available after you have met the minimum viewing requirement and completed the module survey.